Skip to content
Screener

Charles River Laboratories CRL Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$140K+55.6%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$9.15M
Revvity logo
RevvityRVTY
$5.44M+107%
Quest Diagnostics logo
Quest DiagnosticsDGX
$16M+23.1%
NeoGenomics logo
NeoGenomicsNEO
$2.09M+277%
Schrodinger logo
SchrodingerSDGR
$665K

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemSix Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility1,265,258963,363
Payments on long-term debt, revolving credit facility, and finance lease obligations(745,927)(887,706)
Proceeds from exercises of stock options1,6201
Purchase of treasury stock(323,881)(360,484)
Payments of contingent consideration(11,400)(21,822)
Purchase of remaining equity interests of other redeemable noncontrolling interest(19,140)
Other, net(2,607)(6,458)

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's stock issuance proceeds?
Charles River Laboratories (CRL) reported stock issuance proceeds of $397K in Q2 2026.
How has Charles River Laboratories's stock issuance proceeds changed year-over-year?
Charles River Laboratories's stock issuance proceeds increased by 39600.0% year-over-year, from $1K to $397K.
What is the long-term trend for Charles River Laboratories's stock issuance proceeds?
Over 4 years (2021 to 2025), Charles River Laboratories's stock issuance proceeds has grown at a -64.6% compound annual growth rate (CAGR), from $45.65M to $714K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Charles River Laboratories's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude